Prognostic significance of C-MYC dysregulation in esophageal squamous cell carcinoma: a meta-analysis

被引：3

作者：

Shi, Xuejiao ^{[1
]}

Zhou, Renhua ^{[1
]}

Zheng, Leizhen ^{[1
]}

Jiang, Mawei ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Dept Oncol, Xinhua Hosp, Sch Med, Shanghai 200092, Peoples R China

来源：

BIOMARKERS IN MEDICINE | 2020年 / 14卷 / 07期

关键词：

amplification; biomarker; clinicopathological features; C-MYC dysregulation; esophageal squamous cell carcinoma; lymph node metastasis; overall survival; overexpression; prognosis; targeted therapy; DYSPLASIA-ADENOCARCINOMA SEQUENCE; COPY-NUMBER; PROMOTES; AMPLIFICATION; EXPRESSION; OVEREXPRESSION; EPIDEMIOLOGY; SIGNATURE; PROTEIN; TARGET;

D O I：

10.2217/bmm-2019-0294

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Aim: The clinicopathological and prognostic significance of C-MYC dysregulation (amplification or overexpression) in esophageal squamous cell carcinoma (ESCC) remains controversial. Therefore, we performed this meta-analysis to elucidate this relationship. Materials & methods: Available studies were retrieved from PubMed, Web of Science, EMBASE and the Cochrane Library, and ten studies with a total of 1432 patients were included in this meta-analysis. Results: Pooled results showed that C-MYC dysregulation was significantly associated with poor overall survival (hazard ratio: 1.405 [95% CI: 1.170-1.639]; p < 0.001) and lymph node metastasis (odds ratio: 1.798 [95% CI: 1.125-2.873]; p = 0.014). Subgroup analysis confirmed the results and more prominent predictive effects were observed in the C-MYC amplification group. Conclusion: C-MYC dysregulation is a promising biomarker for ESCC prognosis.

引用

页码：599 / 610

页数：12

共 44 条

[1]

[Anonymous], 2019, CANCER LETT, DOI DOI 10.1016/J.CANLET.2018.10.041

[2]

[Anonymous], 2012, CANCER SCI, DOI DOI 10.1111/J.1349-7006.2012.02329.X

[3]

[Anonymous], 2002, STAT MED

[4]

[Anonymous], 2018, CANCER LETT, DOI DOI 10.1016/J.CANLET.2018.01.051

[5]

[Anonymous], 2016, STEM CELLS, DOI DOI 10.1002/STEM.2395

[6]

[Anonymous], 2013, CANCER METAB, DOI DOI 10.1186/2049-3002-1-7

[7]

[Anonymous], 2016, EXPERT OPIN INV DRUG, DOI DOI 10.1517/13543784.2016.1163336

[8]

[Anonymous], 2017, CANCER RES, DOI DOI 10.1158/0008-5472.CAN-15-2906

[9]

[Anonymous], 2012, CELL, DOI DOI 10.1016/J.CELL.2012.03.003

[10]

[Anonymous], 2007, TRIALS, DOI DOI 10.1186/1745-6215-8-16

← 1 2 3 4 5 →